| Howard Boltansky, MD | |
|
3301 New Mexico Ave Nw, Suite 223, Washington, DC 20016-3622 | |
| (202) 966-7100 | |
| (202) 966-2196 |
| Full Name | Howard Boltansky |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 46 Years |
| Location | 3301 New Mexico Ave Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689745044 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | MD14490 (District Of Columbia) | Secondary |
| 207Y00000X | Otolaryngology | D22385 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
CardioNet, Inc. announced today that the U.S. Patent and Trademark office has granted patent number 7,587,237 ("Biological Signal Management") to CardioNet. The patent includes certain systems and techniques utilized by the Company's Mobile Cardiac Outpatient Telemetry™ (MCOT™) system that automatically processes complex physiological information to make it useful for clinical decisions.
Stories about doping - using performance-enhancing drugs - among professional and Olympic athletes have been regular fodder for the news media in recent years, but what about the trend in use by younger, more vulnerable high school-aged athletes?
Researchers affiliated with the University of Campinas in São Paulo State, Brazil, have shown that genetic information can be used to improve early prediction of the response to drugs in patients with mesial temporal lobe epilepsy (MTLE), one of the most severe forms of epilepsy.
The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.
Research from the University of Kent, the Research center on Interactive Media, Smart systems and Emerging technologies - RISE Ltd and the University of Cyprus has revealed that Virtual Reality technology can have significant impact on the validity of remote health appointments for those with eating disorders, through a process called Virtual Reality Exposure Therapy.
› Verified 2 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
CardioNet, Inc. announced today that the U.S. Patent and Trademark office has granted patent number 7,587,237 ("Biological Signal Management") to CardioNet. The patent includes certain systems and techniques utilized by the Company's Mobile Cardiac Outpatient Telemetry™ (MCOT™) system that automatically processes complex physiological information to make it useful for clinical decisions.
Stories about doping - using performance-enhancing drugs - among professional and Olympic athletes have been regular fodder for the news media in recent years, but what about the trend in use by younger, more vulnerable high school-aged athletes?
Researchers affiliated with the University of Campinas in São Paulo State, Brazil, have shown that genetic information can be used to improve early prediction of the response to drugs in patients with mesial temporal lobe epilepsy (MTLE), one of the most severe forms of epilepsy.
The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.
Research from the University of Kent, the Research center on Interactive Media, Smart systems and Emerging technologies - RISE Ltd and the University of Cyprus has revealed that Virtual Reality technology can have significant impact on the validity of remote health appointments for those with eating disorders, through a process called Virtual Reality Exposure Therapy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Howard Boltansky, MD 6201 Greenleigh Ave, Middle River, MD 21220-2004 Ph: (410) 933-6423 | Howard Boltansky, MD 3301 New Mexico Ave Nw, Suite 223, Washington, DC 20016-3622 Ph: (202) 966-7100 |
News Archive
CardioNet, Inc. announced today that the U.S. Patent and Trademark office has granted patent number 7,587,237 ("Biological Signal Management") to CardioNet. The patent includes certain systems and techniques utilized by the Company's Mobile Cardiac Outpatient Telemetry™ (MCOT™) system that automatically processes complex physiological information to make it useful for clinical decisions.
Stories about doping - using performance-enhancing drugs - among professional and Olympic athletes have been regular fodder for the news media in recent years, but what about the trend in use by younger, more vulnerable high school-aged athletes?
Researchers affiliated with the University of Campinas in São Paulo State, Brazil, have shown that genetic information can be used to improve early prediction of the response to drugs in patients with mesial temporal lobe epilepsy (MTLE), one of the most severe forms of epilepsy.
The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.
Research from the University of Kent, the Research center on Interactive Media, Smart systems and Emerging technologies - RISE Ltd and the University of Cyprus has revealed that Virtual Reality technology can have significant impact on the validity of remote health appointments for those with eating disorders, through a process called Virtual Reality Exposure Therapy.
› Verified 2 days ago
George Zalzal, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-884-2159 | |
Ronak Dixit, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 106 Irving St Nw Ste 2700, Washington, DC 20010 Phone: 202-877-6733 Fax: 202-877-8439 | |
Dr. Richard William Thomas, M.D., D.D.S., M.S. Otolaryngology Medicare: Medicare Enrolled Practice Location: 111 Army Pentagon, Room 2e461, Washington, DC 20310 Phone: 703-693-1909 Fax: 703-693-7072 | |
Michael Joseph Reilly, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-8186 | |
Shaum Sridharan, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Suite 300, Eye & Ear Institute, Washington, DC 20007 Phone: 202-444-1351 | |
Dr. Ameet Singh I, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2150 Pennsylvania Ave Nw, Floor 6b-412, Washington, DC 20037 Phone: 202-741-3437 Fax: 202-741-3218 | |
Dr. Steven Bielamowicz, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2300 M St Nw Fl 4, Washington, DC 20037 Phone: 202-741-3260 Fax: 202-741-3218 |